vimarsana.com

அல்லாத ப்ரிஸ்க்ரிப்ஶந் ஆரோக்கியம் ப்ராடக்ட்ஸ் இயக்குநரகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |MGC Pharmaceuticals Announcements | MGC Pharmaceuticals: Quarterly Results

Investegate |MGC Pharmaceuticals Announcements | MGC Pharmaceuticals: Quarterly Results
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Glow LifeTech Reports on Additional Research Results on ArtemiC and

Article content The results, announced on May 7, 2021, demonstrate the mechanism of action of ArtemiC™ is to reduce inflammation and suppress the cytokine storm 2 – believed to be the one of the leading causes of mortality in COVID-19 patients 3. The results show that ArtemiC™ decreases the markers of inflammation (IFN-g, IL-1a and TNF-a), in the bronchoalveolar lavage fluid (BALF) of mice in the animal model of cytokine storm related to COVID-19. The clinical and preclinical results to date support ArtemiC™ being effective for addressing cytokine overproduction which is found in different variants and mutations of COVID-19. “ArtemiC™ focuses on preventing and reducing the severity of the cytokine storm and hyper-inflammation induced by respiratory viruses, and since all current COVID-19 variants of concern may lead to a cytokine storm, the preclinical and clinical results support that ArtemiC™ should be effective on COVID-19 variants,” said Tom Glawdel, PhD, Chi

Glow LifeTech Announces Successful First Commercial Production of ArtemiC(TM) for Global Distributor and a Second Production Scaled to Meet Growing Global Demand

Glow LifeTech Announces Successful First Commercial Production of ArtemiC(TM) for Global Distributor and a Second Production Scaled to Meet Growing Global Demand
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.